Previous 10 |
SAN FRANCISCO, March 11, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq: EIDX ) today announced that management is scheduled to participate in a fireside chat regarding Eidos at the 31 st Annual ROTH Conference on Monday, March 18 th at 8:30 a.m. PDT in Orange Count...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Ole Andreas Halvorsen...
The following slide deck was published by Eidos Therapeutics in conjunction with this Read more ...
Eidos Therapeutics (NASDAQ: EIDX ) initiates a Phase 3 clinical trial, ATTRibute-CM, evaluating lead candidate AG10 in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). More news on: Eidos Therapeutics, Healthcare stocks news, Read more ...
ATTRibute-CM study design, which incorporates feedback from the FDA, has the potential to accelerate registration with a 12-month primary endpoint of change in 6-minute walk distance (6MWD), followed by a 30-month endpoint of mortality and cardiovascular-related hospitalizations Trial...
SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it will host an investor ...
SAN FRANCISCO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present at two upcoming investor conferences. SVB Leerink Global Healthcare Conference The company will present on Thursday, February 28, 2019 a...
Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself i...
News, Short Squeeze, Breakout and More Instantly...
Eidos Therapeutics Inc. Company Name:
EIDX Stock Symbol:
NASDAQ Market:
Eidos Therapeutics Inc. Website:
PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common st...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve ...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by Br...